NuCana PLC is a clinical-stage biopharmaceutical company based in Edinburgh, UK, focused on pioneering innovative therapies for cancer treatment. Leveraging its proprietary ProTide technology platform, NuCana aims to enhance the efficacy and safety of existing chemotherapy agents while addressing unmet medical needs in oncology. The company's lead product candidates are in various stages of clinical development, targeting a range of cancers, including colorectal and pancreatic cancer. With a commitment to improving patient outcomes through cutting-edge research, NuCana is positioned as a key player in the evolving landscape of cancer therapeutics.